Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Institute Of Cancer Research: Royal Cancer Hospital (The) currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. The busiest examiner for this portfolio is MACH, ANDRE, who is handling 1 busiest examiner pending office action.
With 1 pending office action and 1 distinct examiner, the prosecution process is centralized. The practitioner interacts with MACH, ANDRE for the 1 busiest examiner pending office action. The 1 distinct art unit indicates that the technical subject matter is being evaluated within a single specialized group at the patent office.
The concentration of the 1 pending office action under 1 distinct examiner allows for a targeted prosecution approach. The practitioner does not need to coordinate between multiple examiners or art units for this portfolio. The Biotechnology & Pharmaceuticals technology area designation and the 1 distinct art unit provide the technical context.
The outcome of the current filings depends on the evaluation by the assigned examiner. Practitioners should prioritize the specific art unit protocols relevant to the subject matter. This arrangement supports a prosecution strategy based on direct engagement with the examiner stated concerns.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WAX, ROBERT A | 1 | 25.0% | +3.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17909279 | PHARMACEUTICAL FORMULATIONS COMPRISING 6-CHLORO-7-(4-(4-CHLOROBENZYL)PIPERAZIN-1 -YL)-2-(1,3-DIMETHYL-1 HPYRAZOL-4-YL)-3H- IMIDAZO[4,5-B]PYRIDINE | WAX, ROBERT A | 14d |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17909279 | PHARMACEUTICAL FORMULATIONS COMPRISING 6-CHLORO-7-(4-(4-CHLOROBENZYL)PIPERAZIN-1 -YL)-2-(1,3-DIMETHYL-1 HPYRAZOL-4-YL)-3H- IMIDAZO[4,5-B]PYRIDINE | WAX, ROBERT A | 1615 | §103 | Non-Final OA | 14d | Pending | Sep 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial